Competitive inhibition of heparinase by persulfonated glycosaminoglycans: a tool to detect heparin contamination
Research article published in Analytical chemistry (2011)
Abstract
Heparin and the low molecular weight heparins are extensively used as medicinal products to prevent and treat the formation of venous and arterial thrombi. In early 2008, administration of some heparin lots was associated with the advent of severe adverse effects, indicative of an anaphylactoid-like response. Application of orthogonal analytical tools enabled detection and identification of the contaminant as oversulfated chondroitin sulfate (OSCS) was reported in our earlier report. Herein, we investigate whether enzymatic depolymerization using the bacterially derived heparinases, given the structural understanding of their substrate specificity, can be used to identify the presence of OSCS in heparin. We also extend this analysis to examine the effect of other persulfonated glycosaminoglycans (GAGs) on the action of the heparinases. We find that all persulfonated GAGs examined were effective inhibitors of heparinase I, with IC(50) values ranging from approximately 0.5-2 μg/mL. Finally, using this biochemical understanding, we develop a rapid, simple assay to assess the purity of heparin using heparinase digestion followed by size-exclusion HPLC analysis to identify and quantify digestion products. In the context of the assay, we demonstrate that less than 0.1% (w/w) of OSCS (and other persulfonated polysaccharides) can routinely be detected in heparin.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Heparin and the low molecular weight heparins are extensively used as medicinal products to prevent and treat the formation of venous and arterial thrombi.
Por qué esto importa para la hirudoterapia
Este estudio bioquímico encontró que los glicosaminoglicanos persulfonados, incluido el sulfato de condroitina sobresulfado (OSCS) implicado en los eventos adversos de 2008 por heparin contaminada, inhiben competitivamente la heparinasa I bacteriana (IC50 aproximadamente 0.5-2 microgramos/mL), y sobre esta base los autores desarrollaron un ensayo de digestión con heparinasa más HPLC de exclusión por tamaño capaz de detectar menos del 0.1% de contaminación por OSCS en heparin. Es tangencial a la hirudoterapia en sí, pero relevante para el contexto más amplio de anticoagulantes y farmacología enzimática que rastrea la biblioteca de evidencia de ASH, demostrando cómo la especificidad de sustrato de una enzima puede convertirse en una herramienta de control de calidad para un anticoagulante de uso generalizado. Como estudio in vitro de métodos analíticos, valida un ensayo de contaminación y el comportamiento de inhibición de estos compuestos, y no aborda el uso clínico de heparin, sanguijuelas, ni ningún resultado de tratamiento.
Citación
Competitive inhibition of heparinase by persulfonated glycosaminoglycans: a tool to detect heparin contamination
Aich U et al. · Analytical chemistry, 2011
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026